Switzerland· 67046001
Zeposia 0.23 mg, Hartkapseln
A ozanimod product containing ozanimodum, registered in Switzerland by Bristol-Myers Squibb SA and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Ozanimod is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AE02 (ozanimod), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Ozanimod · ATC L04AE02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ozanimod costs, country by country.
Normalised to the WHO defined daily dose (0.92 mg), so markets compare like for like.
- Switzerland: $85.78 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Ozanimod · price per daily dose (0.92 mg)
USD · FX 28 Sept 2026
- CH Switzerland$85.78
The record
At a glance
Swissmedic (Switzerland)- Active substance
- ozanimodum
- Manufacturer
- Bristol-Myers Squibb SA
- Country
- Switzerland (CH)
- ATC code
- L04AE02
- ATC class
- Ozanimod
- Defined daily dose
- 0.92 mg, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680670460019Blist 7 StkCHF 336.1
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
852 interactions on record for ozanimod.
Graded by severity as the source publishes them — 578 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ozanimod · interactions on record
852 records
- 578 severe
- 271 moderate
- 3 minor
Most severe, free to view
- FamotidineA02BA03severe
- PapaverineA03AD01severe
- IsomethepteneA03AX10severe
- CisaprideA03FA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ozanimod in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumZeposia 0.23 mg - 0.46 mgBristol-Myers Squibb Pharma
- SpainZEPOSIA 0,23 MG/0,46 MG CAPSULAS DURASBristol-Myers Squibb Pharma Eeig
- United KingdomZeposia 0.23mg capsulesBristol-Myers Squibb Pharmaceuticals Ltd
- IrelandZeposia 0.23 mg hard capsules Zeposia 0.46 mg hard capsulesBristol-Myers Squibb Pharma EEIG
- IcelandZeposiaBristol-Myers Squibb Pharma EEIG*
- NetherlandsZeposia 0,23 mg capsule, hardBristol-Myers Squibb Pharma EEIG
- NorwayZeposiaBristol-Myers Squibb Pharma EEIG (1)
- SwedenZeposia 0,23 mg + 0,46 mg Kapsel, hårdBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zeposia
- Liechtenstein · Zeposia
- Norway · Zeposia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b02ea58e-852c-4727-b356-c5b14dafb4a2 GET /v1/drugs/b02ea58e-852c-4727-b356-c5b14dafb4a2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "ozanimodum 0.46 mg",
"valid_from": "2023-09-01",
"limitations": "[{\"description\":\"Behandlung von schubförmig remittierender multipler Sklerose (MS). Erstverschreibung durch den Facharzt FMH für Neurologie.<br>\\n<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21065.01<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21065.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2023-09-01\"},{\"description\":\"ZEPOSIA ist zur Behandlung von erwachsenen Patienten mit mittelschwerer bis schwerer aktiver Colitis Ulcerosa (CU) indiziert, die entweder auf konventionelle Therapien oder die Behandlung mit einem Biologikum ungenügend angesprochen haben, nicht mehr ansprechen oder die Therapie nicht tolerierten.<br>\\nBei Patienten, bei denen bis zur Woche 10 kein klinisches Ansprechen festzustellen ist, sollte die Therapie abgebrochen werden.<br>\\nDie Anwendung von ZEPOSIA in Kombination mit biologischen Wirkstoffen und/oder starken Immunsuppressiva wird nicht vergütet.<br>\\nEine Weiterbehandlung mit ZEPOSIA nach einer Therapiedauer von einem Jahr bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\nDie Bristol-Myers Squibb SA erstattet in der Indikation Colitis Ulcerosa dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin für jede bezogene Packung ZEPOSIA einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückerstattung bekannt.<br>\\nDie Mehrwertsteuer kann nicht zusätzlich zu den Rückvergütungsbeträgen zurückgefordert werden.<br>\\nDie Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\n<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21065.02<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21065.02\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2024-10-01\",\"validTo\":\"2026-09-30\"}]",
"galenic_form": "Kaps 4 x 0.23 mg 3 x 0.46 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2020-09-01",
"self_retention_pct": 10
}See everything about ozanimod.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.